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Abstract
Background: Few low-income countries have virological monitoring widely available. We estimated the virological
durability of first-line antiretroviral therapy (ART) after five years of follow-up among adult Ugandan and Zimbabwean
patients in the DART study, in which virological assays were conducted retrospectively.
Methods: DART compared clinically driven monitoring with/without routine CD4 measurement. Annual plasma
viral load was measured on 1,762 patients. Analytical weights were calculated based on the inverse probability of
sampling. Time to virological failure, defined as the first viral load measurement ≥200 copies/mL after 48 weeks of
ART, was analysed using Kaplan-Meier plots and Cox regression models.
Results: Overall, 65% of DART trial patients were female. Patients initiated first-line ART at a median (interquartile
range; IQR) age of 37 (32–42) and with a median CD4 cell count of 86 (32–140). After 240 weeks of ART, patients
initiating dual-class nucleoside reverse-transcriptase inhibitor (NRTI) -non-nucleoside reverse-transcriptase (NNRTI)
regimens containing nevirapine + zidovudine + lamivudine had a lower incidence of virological failure than patients
on triple-NRTI regimens containing tenofovir + zidovudine + lamivudine (21% vs 40%; hazard ratio (HR) =0.48,
95% CI:0.38–0.62; p < 0.0001). In multivariate analyses, female patients (HR = 0.79, 95% CI: 0.65–0.95; p = 0.02),
older patients (HR = 0.73 per 10 years, 95% CI: 0.64–0.84; p < 0.0001) and patients with a higher pre-ART CD4
cell count (HR = 0.64 per 100 cells/mm3, 95% CI: 0.54–0.75; p < 0.0001) had a lower incidence of virological
failure after adjusting for adherence to ART. No difference in failure rate between the two randomised
monitoring strategies was observed (p= 0.25).
Conclusions: The long-term durability of virological suppression on dual-class NRTI-NNRTI first-line ART without
virological monitoring is remarkable and is enabled by high-quality clinical management and a consistent drug
supply. To achieve higher rates of virological suppression viral-load-informed differentiated care may be required.
Trial Registration: Prospectively registered on 18/10/2000 as ISRCTN13968779.
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Background
The treatment of human immunodeficiency virus (HIV)
in low-income countries has predominantly followed a
“public health approach” as access to antiretroviral therapy
(ART) has been scaled up [1, 2]. This approach recom-
mends standardised treatment regimens and a simplified
approach for monitoring patients on ART. The World
Health Organisation (WHO) guidelines for the treatment
of HIV are regularly updated and in 2010 [3] recom-
mended that patients receive regular clinical and immuno-
logical monitoring whilst on treatment. Additionally, if
resources permit, they advised that viral load should be
used in a targeted approach to confirm treatment failure
detected either immunologically or clinically. The 2013
guidelines [4] were updated to strongly recommend HIV
viral load monitoring six months after initiating ART and
then every twelve months, although noted that this strong
recommendation was based on low-quality evidence. Des-
pite a paucity of evidence, there remains a widespread
anxiety that without virological monitoring patients may
remain on a treatment regimen that they are virologically
failing for a sustained period of time. This could lead to
worse long-term clinical outcomes and potentially the ac-
cumulation of drug-resistance mutations that compromise
second-line ART (although it is noteworthy that substan-
tial cross-resistance did not impair response to second-
line in the EARNEST trial [5]). Furthermore, there are
concerns that immunological criteria for switching treat-
ment have low specificity and can lead to unnecessary
treatment switches to more expensive second-line regi-
mens, which in low-income settings may be the last
available treatment option.
Individual countries are deciding, within financially-
restricted healthcare systems, whether they should invest
in upgrading laboratory infrastructure to facilitate viro-
logical monitoring. Currently, despite 39/52 low and
middle-income countries recommending viral load test-
ing, in only 8/52 has testing become widely available [6].
Cost-effectiveness studies have evaluated the potential
trade-offs between expanding access to ART to more pa-
tients, viral load versus CD4 monitoring and alternative
monitoring frequencies for patients and through viral-
load-informed differentiated care [7]. Keebler et al. [8]
concluded that “viral load monitoring should only be con-
sidered after high antiretroviral therapy coverage has been
achieved”, for example by raising the CD4 threshold at
which ART is initiated. More recently, a working group
on modelling of ART monitoring strategies in Sub-
Saharan Africa [7] found that through the use of dried
blood sample testing and tailored care, such as patients
with suppressed viral load visiting clinics less frequently, a
cost-effective strategy was possible. A critical parameter
for cost-effectiveness models is the rate of virological fail-
ure. To date, this has been entirely estimated from cohorts
that received regular viral load monitoring, which may not
reflect the experience of the majority of patients who have
been treated in settings without laboratory monitoring.
In this analysis, we report longitudinal findings from
the DART trial on the virological durability of first-line
ART over 240 weeks of follow-up among adult Ugandan
and Zimbabwean patients without real-time viral load
monitoring.
Methods
Study overview
DART was a randomised open-label non-inferiority trial
conducted in ART-naïve, symptomatic HIV-infected
adults with a CD4 cell count ≤200 cells/mm3. DART en-
rolled from three clinical centres in Uganda and one in
Zimbabwe. Recruitment was between January 2003 and
October 2004 and patients were followed until the end of
2008 [9]. Patients were randomised to clinically-driven
monitoring only (CDM) or clinical monitoring plus routine
laboratory monitoring (LCM) in the form of twelve-weekly
CD4 and haematological/biochemical toxicity tests. CD4
cell count results were not returned to patients in the
CDM arm. At each visit a plasma sample was stored; real-
time viral load monitoring was not conducted during
DART. Patients were switched to a second-line regimen
containing a ritonavir-boosted protease inhibitor (PI) if a
new or recurrent WHO stage 4 event occurred. Alterna-
tively, patients could switch at the clinician’s discretion if
one or more WHO stage 3 events occurred (such as can-
didiasis or weight loss). Additionally, in the LCM arm, pa-
tients could switch treatment if there was a confirmed CD4
cell count <100 cells/mm3 (<50 cells/mm3 prior to July
2006). Switching treatment before 48 weeks was strongly
discouraged for patients on both monitoring strategies.
The DART trial was approved by research ethics commit-
tees in Uganda, Zimbabwe, and the UK. Patient consent in-
cluded the storage of plasma samples and later testing.
Three different first-line ART regimens were used in
the DART study. All patients received co-formulated
zidovudine (ZDV) and lamivudine (3TC). In a Ugandan
substudy [10], 600 patients were randomised to receive
either abacavir (ABC, n = 300) or nevirapine (NVP, n =
300). An additional 247 patients in Zimbabwe received
open-label NVP. All other patients (n = 2,469) received a
triple-nucleoside reverse-transcriptase inhibitor (NRTI)
regimen, which included the third drug tenofovir (TDF).
Sample storage
Whole bloods were collected in EDTA vacutainers at rou-
tine visits during DART follow up and plasma isolated by
centrifugation within 2 to 6 h following local laboratory
procedures. Plasma was distributed into 2 ml cryovials as
1 ml to 1.5 ml aliquots and stored frozen at minus 80 °C
until retrieval for HIV viral load assays.
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Sample selection
Viral load testing was conducted on approximately 3,500
of the 60,000 plasma samples held in the DART reposi-
tory. Patients were excluded completely if (a) they either
died or switched treatment prior to week 48, since early
deaths were unlikely to be due to treatment failure [11]
and early switches were rare and discouraged, or (b) re-
ceived a structured treatment interruption [12], because
these are no longer recommended in treatment guidelines.
All other patients who received either NVP (n = 404) or
ABC (n = 254) were selected, as well as a sample of pa-
tients who received TDF (n = 1,104). This sample select-
ively included patients who received a viral load test under
a national Ugandan viral load testing program shortly after
trial closure [13]. Further details on the sampling process
are included in Additional file 1.
Plasma samples for viral load testing from this sample
of patients were selected using a “walkback” procedure,
beginning with the last sample on first-line ART. If viral
load was <200 copies/mL no further samples were tested;
if not, a sample from approximately 48 weeks earlier was
tested. This process was repeated at approximate 48-week
intervals until a result <200 copies/mL was obtained or
until the week 48 sample was tested. In addition, samples
from baseline (week 0) were tested in 74% of patients; the
24% baseline samples not tested were from those on TDF
known to be suppressed at the end of the study via the na-
tional Ugandan testing program.
Statistical methods
To correct for non-random sampling, analytical prob-
ability weights based on the inverse probability of a pa-
tient being sampled, were used in all analyses to reflect
the DART population as a whole [14]. Time to persistent
virological failure, defined as the first viral load measure-
ment ≥200 copies/mL after 48 weeks of ART, was ana-
lysed using adjusted Kaplan-Meier estimators and Cox
regression models (stratified by study centre) incorporat-
ing the analytical weights [15]. Non-proportionality was
investigated using Schoenfeld residuals and continuous
variables were included in the Cox model using a multi-
variable fractional polynomial model [16]. In the primary
analysis, patients were censored at the time of switch to
second-line ART or death if they had not virologically
failed by this time. In a sensitivity analysis we considered
all deaths and ART switches after 48 weeks of ART as
virological failures regardless of their viral load at the
time of the event. A second sensitivity analysis consid-
ered all deaths and ART switches as virological failures.
A final sensitivity analyses investigated the effect of alter-
native definitions of virological failure. Adherence was
included as a time-dependent covariate summarizing
the estimated adherence in each 48 week period, as
measured by the proportion of visits where pill counts
indicated greater than 95% drug possession ratio (de-
fined as the days’ supply of drugs delivered minus the
days’ supply of drugs returned divided by the number
of days between clinic visits) [17].
To avoid a loss in efficiency, missing values for base-
line viral loads on the log10 scale were multiply imputed
30 times using a linear regression model which included
all potential prognostic factors (terms of Cox model)
and outcome variables (Nelson-Aalen estimator for time
to virological failure, censoring indicator) [18]. This as-
sumes that missing values do not depend on unobserved
variables conditional on the observed data, such as the
outcome variable. Analyses were performed on each im-
puted dataset and the imputation-specific coefficients
combined using Rubin’s rules. All analyses were con-
ducted using Stata 13.1 [19].
Results
Baseline characteristics
Baseline characteristics for patients included in the over-
all DART trial and viral load substudy are shown in
Table 1. Overall, 65% of DART trial patients were fe-
male. Patients initiated first-line ART at a median (inter-
quartile range (IQR)) age of 37 (32–42) years and with a
median CD4 cell count of 86 (32–140) cells/mm3. Over-
all 17% of patients received a dual-class NRTI/non-NRTI
(NNRTI) regimen and 83% received a triple-NRTI regi-
men. Characteristics were broadly similar in the viral
load substudy apart from first-line ART (patients pre-
scribed NVP or ABC over-represented in the substudy
by design) and study centre (Kampala over-represented
and Harare under-represented by design). However,
the use of analytical weights (see Statistical methods)
corrects for these design imbalances.
Durability of virological suppression
Overall, one or more viral load measurements were
available for 1,741/1,762 (99%) patients. The first sam-
ple tested (last time point on first-line ART) was after a
median (IQR) 252 (224–280) weeks on first-line ART.
In total, 606 patients (35%) were observed to fail viro-
logically during follow-up. Figure 1 displays the cumu-
lative percentage with virological failure over time, by
first-line ART received. At 48 weeks, 19% (95% confi-
dence interval (CI): 17–20%) of patients had virological
failure - approximately half of all failures which oc-
curred by 240 weeks. Most treatment switches occurred
with virological failure (83%) and second-line switches
with treatment failure were more likely in the LCM
arm (128/145; 88% compared to 94/122; 77%; p = 0.02).
Overall, an estimated 28% (95% CI: 26–29%) of patients
had experienced virological failure by 96 weeks, 32%
(95% CI: 31–34%) by 144 weeks, 35% (95% CI: 33-37%)
by 192 weeks and 37% (95% CI: 35–39%) by 240 weeks.
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The rate of virological failure was similar for patients
receiving triple-NRTI regimens containing either TDF
or ABC (40% (95% CI: 38–42%) and 45% (95% CI: 38–
50%) respectively at 240 weeks; p = 0.37), but was sub-
stantially lower for patients who received a dual-class
regimen containing NVP (21% (95% CI: 18–25%) at
240 weeks; p < 0.0001).
There was no evidence that monitoring strategy af-
fected long-term virological failure in the multivariable
Cox model (Table 2) (p = 0.25). However, both gender
and age were strong predictors of virological failure. Fe-
male patients had a 21% lower incidence of virological
failure (p = 0.01) and each additional 10 year increase in
a patient’s age reduced incidence of virological failure by
Table 1 Patient characteristics, overall and patients sampled for viral load substudy
Factor Overall Viral load substudy
Monitoring randomisation
LCM 1,502 (50%) 882 (50%)
CDM 1,505 (50%) 880 (50%)
Gender
Male 1,051 (35%) 587 (33%)
Female 1,956 (65%) 1,175 (67%)
Age at ART initiation (years) Median (IQR) 37 (32 – 42) 37 (32 – 43)
CD4 at ART initiation (cells/mm3)
Median (IQR) 86 (32 – 140) 83 (31 – 137)
0-49 996 (33%) 585 (33%)
50-99 725 (24%) 440 (25%)
100-149 687 (23%) 400 (23%)
150-200 599 (20%) 337 (19%)
Viral load at ART initiation (copies/mL)
Missing - 452 (26%)
<30,000 - 132 (10%)
30,000 – 100,000 - 181 (10%)
100,000 – 300,000 - 373 (21%)
300,000 – 700,000 - 340 (19%)
>700,000 - 284 (16%)
First-line ARTa
TDF 2,196 (73%) 1,104 (63%)
NVP 520 (17%) 404 (23%)
ABC 291 (10%) 254 (14%)
TB in 12 months prior to enrolment 737 (25%) 421 (24%)
Centre
Entebbe, Uganda 914 (30%) 543 (31%)
Kampala, Uganda 1,159 (39%) 809 (46%)
Harare, Zimbabwe 934 (31%) 410 (23%)
Adherence at week 48
0 – 50% 106 (4%) 68 (4%)
50 – 67% 175 (6%) 108 (6%)
67 – 75% 251 (8%) 152 (9%)
75 – 83% 456 (15%) 264 (15%)
83 – 92% 876 (29%) 523 (30%)
>92% 1,134 (38%) 645 (37%)
Missing 9 (0%) 2 (0%)
aIn conjunction with co-formulated AZT/3TC
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27% (Fig. 2; p < 0.0001). Each additional 100 cell increase
in patient’s baseline (pre-ART) CD4 cell count reduced
incidence of virological failure by 36% (p < 0.0001).
There was no evidence that baseline viral load affected
the incidence of virological failure (p = 0.89). The multi-
variable fractional polynomial model revealed no evi-
dence of non-linearity and there was no evidence of
non-proportionality for either monitoring strategy or
initial ART. Compared with the TDF reference group,
patients who received a NVP-containing regimen had a
52% (p < 0.0001) lower incidence of virological failure
and patients prescribed ABC a 27% (p = 0.03) higher in-
cidence of virological failure. Adherence, as measured by
the proportion of visits in the past 48 weeks where the
drug possession ratio was >95%, showed clear associ-
ation with virological failure, with 11% lower incidence
of virological failure for every 10% increase in the pro-
portion of adherent visits (p < 0.0001).
Fig. 1 Cumulative percentage with virological failure (viral load > 200 copies/mL) by first-line ART regimen. Figure shows cumulative percentage
with virological failure estimated using the Kaplan-Meier method incorporating analytical weights. Number at risk = number of patients alive
and on continuous first-line ART without virological failure
Table 2 Cox regression analysis of predictors of virological failure
Factor Univariable HR p-value Multivariable HR (95% CI) p-value
Monitoring randomisation
LCM 1.00 - 1.00 -
CDM 1.07 0.45 1.11 (0.93 - 1.35) 0.25
Gender
Male 1.00 - 1.00 -
Female 0.80 0.02 0.79 (0.65 - 0.95) 0.01
Initial ART
TDF 1.00 <0.0001 1.00 <0.0001
NVP 0.49 - 0.48 (0.38 - 0.62) -
ABC 1.18 - 1.27 (1.02 - 1.59) -
TB in 12 months prior to enrolment 1.13 0.26 1.07 (0.86 - 1.33) 0.52
Age (per 10 years older) 0.73 <0.0001 0.73 (0.64 - 0.84) <0.0001
Baseline CD4 (per 100 cells/mm3 higher) 0.60 <0.0001 0.64 (0.54 - 0.75) <0.0001
Baseline viral load (log10 copies/mL) 1.02 0.84 1.01 (0.84 - 1.22) 0.89
Adherence in previous 48 weeksa (per 10% higher) 0.89 <0.0001 0.89 (0.84 - 0.94) <0.0001
atime-updated
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Previous research suggests that ABC-based regimens
may be more prone to failure for baseline viral loads ≥
100,000 copies/mL [20]. A test for interaction indicated
that there was an association between initial ART and a
baseline viral load ≥ 100,000 copies/mL in this data (p =
0.02). Patients on ABC with a baseline viral load <
100,000 copies/mL had a 48% (95% CI: 18–68%) lower
incidence of virological failure compared to those with a
baseline viral load ≥ 100,000 copies/mL. However, this
effect was much less marked for patients who received
TDF (20% lower incidence, 95% CI −8–41%) or NVP
(13% lower incidence, 95% CI −41–46%).
Sensitivity analyses
The first sensitivity analysis, which considered all deaths
and ART switches (n = 86) after 48 weeks as virological
failures, slightly increased the cumulative incidence of
virological failure (41% by 240 weeks) but had a negli-
gible effect on the multivariable hazard ratios (HR)
(Table 3). Secondly, assuming that deaths and ART
switches prior to week 48 (n = 172) were also virological
failures increased the overall cumulative incidence of viro-
logical failure to 41% by 240 weeks and for patients on
dual-class regimens containing nevirapine to 24%. Finally,
alternative thresholds for virological failure were investi-
gated. Using a threshold of >1,000 copies/mL did not ma-
terially change our findings but increasing the threshold to
>10,000 copies/mL led to a similar incidence of virological
failure for patients on ABC compared to TDF. This sug-
gests that the differences in failure rates between patients
on ABC and TDF are driven by a higher proportion of
patients on ABC failing with a viral load between 200 and
10,000 copies/mL.
Discussion
This analysis found that at 240 weeks an estimated 79%
of patients on dual-class regimens in the DART study
were virologically suppressed. This was particularly note-
worthy given that the overall median CD4 cell count when
ART was initiated was 86 cells/mm3 and a third had <50
cells/mm3. Persistent undetected virological failure was
relatively low (20%); high virological failure rates are
not an inevitable consequence of using only clinical or
CD4 cell count monitoring. Within financially-restricted
healthcare systems the lack of availability of virological
monitoring should not limit countries when expanding
access to ART. However, to achieve higher rates of viro-
logical suppression, viral-load-informed differentiated care
may be required [7].
The rate of virological failure in patients who started
ART with a triple-NRTI regimen was approximately
twice that of dual-class regimens. Baseline CD4 cell
count remained a strong predictor of virological failure
after 48 weeks on first-line ART. Despite adjusting for
differences in adherence, both female patients and older
patients had a lower incidence of virological failure.
Comparisons with other studies
A previous cross-sectional analysis of data from Ugandan
centres at the end of the DART study found 80% of pa-
tients who remained on first-line ART had suppressed
viral load (<400 copies/mL) [13]. Virological suppression
was also shown to differ by trial arm (p = 0.003), 76% were
Fig. 2 Cumulative percentage with virological failure (viral load > 200 copies/mL) by age at randomisation. Figure shows cumulative percentage
with virological failure estimated using the Kaplan-Meier method incorporating analytical weights. Number at risk = number of patients alive
and on continuous first-line ART without virological failure
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suppressed in the CDM arm compared to 83% in the
LCM arm. Our research extends this study by including
longitudinal data, data from Zimbabwe and patients who
switched treatment or died during the study. Importantly,
more patients in LCM switched to second-line and were
excluded from this previous analysis: these patients were
also more likely to virologically fail [21]. After including
the greater proportion of patients with virological failure
in the LCM arm who switched to second-line ART we
demonstrated no overall difference by randomised moni-
toring strategy in long-term virological failure.
Even though most patients were receiving triple NRTIs
first-line, we found more durable virological suppression
than a 2015 meta-analysis [22], in which 62% (n = 504) of
adult patients on NNRTI-based regimens in four studies
from low and middle income countries remained viro-
logically suppressed in an intention-to-treat analysis after
48 months of ART. Of those on treatment, 83% (n = 909)
of patients from six studies were virologically suppressed
after 60 months of ART. Unlike our analysis, both of these
estimates did not consider switches to second-line ART as
virological failure. Cost-effectiveness analyses conducted by
Phillips et al. [23] assume that 25% of patients starting
ART for the first time with a boosted PI or NNRTI regimen
virologically fail by 5 years, slightly higher than our findings
for patients on dual-class regimens containing NVP.
We show that patients on ABC have a higher inci-
dence of virological failure than patients on TDF, in line
with previous research [20, 24] and a meta-regression
analysis [25] comparing these drugs in dual-class regi-
mens containing NNRTI or PIs [20, 24, 26]. Sax et al.
[20] found that there was no difference in time to
virological failure in patients on dual-class regimens
with baseline viral load < 100,000 copies/mL, but that
there was a shorter time to failure in patients on
ABC with baseline viral load > 100,000 copies/mL.
Our analysis shows that this remains true in triple-
NRTI regimens and supports treatment guidelines
which recommend that ABC is only used when base-
line viral load is <100,000 copies/mL.
Some studies [25, 27] have demonstrated that older
patients have a better virological response to ART, al-
though many other studies have found no effect of age
[25]. An improved virological response is often speculated
to be a result of greater adherence in older patients [25].
The age effect in DART persisted after controlling for a
measure of adherence based on pill counts and returns.
However, adherence may be under reported by age so
pharmacologic effects such as decreased metabolism with
older age cannot be excluded.
Women were shown to have significantly lower inci-
dence of virological failure than men after adjusting for
differences in adherence, which has not been widely
shown before. A recent systematic review on sex differ-
ences in HIV outcomes [28] reported a non-significant,
marginally decreased risk of virological failure for female
Table 3 Sensitivity analyses of virological failure definition
Default Sensitivity 1 Sensitivity 3
VF≥ 200 cps/mL VF≥ 200 cps/mL VF≥ 1,000 cps/mL VF≥ 10,000 cps/mL
Multivariable HR
(95% CI)
p-value Multivariable HR
(95% CI)
p-value Multivariable HR
(95% CI)
p-value Multivariable HR
(95% CI)
p-value
Monitoring randomisation
LCM 1.00 - 1.00 - 1.00 - 1.00 -
CDM 1.11 (0.93 – 1.34) 0.25 1.16 (0.98 – 1.38) 0.09 1.14 (0.94 – 1.37) 0.19 1.18 (0.96 – 1.45) 0.11
Gender
Male 1.00 - 1.00 - 1.00 - 1.00 -
Female 0.79 (0.65 – 0.95) 0.01 0.84 (0.70 – 1.01) 0.06 0.78 (0.64 – 0.95) 0.01 0.77 (0.62 – 0.95) 0.02
Initial ART
TDF 1.00 <0.0001 1.00 <0.0001 1.00 <0.0001 1.00 <0.0001
NVP 0.48 (0.38 – 0.62) - 0.49 (0.39 – 0.62) - 0.49 (0.38 – 0.63) - 0.50 (0.38 – 0.65) -
ABC 1.27 (1.02 – 1.59) - 1.23 (0.99 – 1.52) - 1.23 (0.97 – 1.55) - 1.00 (0.76 – 1.31) -
TB in 12 months prior to enrolment 1.07 (0.86 – 1.33) 0.52 1.07 (0.88 – 1.32) 0.47 1.08 (0.86 – 1.36) 0.49 1.15 (0.91 – 1.46) 0.24
Age (per 10 years older) 0.73 (0.64 – 0.84) <0.0001 0.77 (0.68 – 0.88) <0.0001 0.70 (0.61 – 0.81) <0.0001 0.69 (0.60 – 0.80) <0.0001
Baseline CD4 (per 100 cells/mm3
higher)
0.64 (0.54 – 0.75) <0.0001 0.67 (0.57 – 0.78) <0.0001 0.60 (0.50 – 0.72) <0.0001 0.52 (0.43 – 0.64) <0.0001
Baseline viral load (log10 copies/mL) 1.01 (0.84 – 1.22) 0.89 0.99 (0.83 – 1.18) 0.91 1.02 (0.84 – 1.24) 0.82 1.02 (0.82 – 1.25) 0.88
Adherence in previous 48 weeksa
(per 10% higher)
0.89 (0.84 – 0.94) <0.0001 0.90 (0.85 – 0.94) <0.0001 0.89 (0.84 – 0.94) <0.0001 0.88 (0.82 – 0.94) <0.0001
atime-updated
Dolling et al. BMC Infectious Diseases  (2017) 17:160 Page 7 of 10
patients (pooled risk ratio = 0.93; 95% CI = 0.85 – 1.01).
However, a meta-analysis of randomised trials found no
difference in virological outcome at week 48 [29]. In-
accurate reported adherence may account for some of
this difference although pharmacologic effects related to
gender cannot be excluded.
There was no evidence that baseline viral load was
associated with the incidence of virological failure. In
contrast, a meta-analysis [30] has demonstrated that
patients with baseline viral load >100,000 copies/mL are
less likely to be virologically suppressed after 48 weeks
of treatment. The lack of association in DART could be
due to the high viral load at baseline (24% of patients in
DART had a baseline viral load ≤ 100,000 copies/mL
compared to 55% in Stephan et al. [30]) and may indi-
cate that the effect plateaus above 100,000 copies/mL.
Additionally, it is also possible that with increased
follow-up the effect of baseline characteristics is dimin-
ished. However, Stephan et al. [30] note that even among
the 21 trials they examined there are inconsistent results
for baseline viral load.
Study limitations
The majority of patients in DART used triple-NRTI
regimens which are no longer used in low-income
countries so findings for these patients are of less inter-
est and included for completion. Nonetheless, this ana-
lysis contains virological outcome data for 404 patients
who used a dual-class regimen containing nevirapine
with 240 weeks of follow-up data. The recent system-
atic review [21] only contained intention-to-treat data
for 504 patients after 24 months of ART so this data
contributes substantially to the existing evidence. Since
the DART trial was conducted in 2010 there has been
increased access to ART in low-income settings and
growing ART-naïve HIV drug resistance. This could
increase the value of viral load monitoring but is not
evaluable in the DART trial population.
Due to funding, only a proportion of patients in DART
could have virological testing conducted. This should
not bias the results since the complete analysis popula-
tion of interest on nevirapine and abacavir were sampled
and a random sample was taken of patients on tenofovir.
Patients were appropriately weighted in all analyses to
account for the sampling method. It is likely that including
patients who died prior to week 48 would increase the
proportion detected with virological failure.
The walkback approach to viral load sampling meant
that intermittent or early virological failure in patients
who subsequently re-suppressed is not detected. The
clinical consequences of intermittent viremia in low-in-
come countries are complex but with limited availability
of second-line regimens in low-income countries the
priority is to achieve long-term virological suppression
on first-line regimens. Including patients with intermit-
tent or virological failure before 48 weeks of ART would
increase the proportion detected with virological failure.
DART was a randomised clinical trial with a high quality
of clinical care, so it could be argued that the sustained
virological suppression observed is not generalizable to
wider clinical settings in resource-limited countries.
Nonetheless, this analysis demonstrates that long-term
virological suppression on dual-class regimens containing
nevirapine is feasible if patients receive regular clinic visits
and have consistent drug supply, despite the absence of la-
boratory monitoring, sub-optimal treatment regimens and
low baseline CD4 cell count.
Analyses of drug resistance assays on the samples in
this study are currently ongoing. Therefore at this stage
we are not able to conclude whether virological failure is
the result of non-adherence to ART or due to HIV-1
drug resistance mutations developing. Similarly, the clinical
consequences of virological failure are also being investi-
gated in ongoing analyses.
Conclusions
Our analysis longitudinally examines virological failure
in a setting without virological monitoring over five years
of follow-up. The rate of virological failure is lower than a
recent systematic review, particularly given that most
patients received less potent triple-NRTI regimens. Our
results suggest that within financially-restricted healthcare
systems, virological control is achievable in the absence of
real time viral load testing, and that a consistent drug sup-
ply, enabling high levels of adherence, is likely more cru-
cial for sustained virological suppression than upgrading
clinical and laboratory infrastructure. To achieve higher
rates of long-term virological suppression, viral-load
informed differentiated care may be required.
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